GSK plc GSK
48.70 USD -0.43 (-0.88%)
At closeNov 3, 2026, 4:58 PM EST
49.67 +0.97 +1.99%
After hours · Nov 3, 4:58 PM ET
48.63 Day range 49.57
45.81 52-week range 61.70
- YTD
- -0.69%
- 1 year
- +5.07%
News
benzinga.com Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc…
globenewswire.com Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a…
seekingalpha.com GSK: The Gas Pedal Is Still Down, But Bumps Ahead Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines…
benzinga.com Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9 Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
zacks.com GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
seekingalpha.com GSK plc (GSK) Q3 2026 Earnings Call Transcript GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director…
marketbeat.com What GSK (GSK) Said on Its Q3 Earnings Call GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit…
zacks.com GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
benzinga.com GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.
benzinga.com GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs offset vaccine drops. 2026 outlook reaffirmed.
seekingalpha.com GSK: Why I'm Still Bullish After Strong Q3 Results GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641…
benzinga.com UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
benzinga.com GSK Q3 2026 Earnings Call Transcript GSK (NYSE:GSK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com GSK (GSK) Q3 Earnings and Revenues Beat Estimates GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.
wsj.com GSK Sales Get Boost From Specialty Medicines The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.- benzinga.com GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.78 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.150 billion…
benzinga.com GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
reuters.com GSK beats third-quarter profit estimates, keeps annual targets GSK beat third-quarter sales and profit expectations on Wednesday, helped by demand for specialty medicines, suggesting CEO Luke Miels' efforts to accelerate growth and prepare the drugmaker for
seekingalpha.com GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
benzinga.com Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco…
marketbeat.com GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC…
benzinga.com Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4 Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results…
reuters.com GSK to nearly double cancer drugs in trials, WSJ reports GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, the Wall Street Journal reported on Tuesday, citing an interview with a scientist
wsj.com GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.- benzinga.com GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma Patients receiving Ris-Rez remained progression-free for a median of 5.5 months versus 1.4 months with comparatorSecond positive phase III trial in China adds to growing body of late-stage evidence…
benzinga.com Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathologyNo disease recurrences reported among responders after median…
247wallst.com Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28? GSK (NYSE:GSK | GSK Price Prediction) reports third-quarter results on October 28. A $2.
zacks.com Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com GSK Wins FDA Approval For Chronic Hepatitis B Drug FDA clears GSK Hibsago for chronic hepatitis B in adults, delivering strong functional cure rates and suppressing viral replication targets.
proactiveinvestors.com GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The…
businesswire.com Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B…
reuters.com US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
zacks.com GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.
benzinga.com FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated FDA approves GSK's Jemperli as first immunotherapy for dMMR/MSI-H rectal cancer, offering a surgery-free alternative.
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Analysts review high-yield healthcare stocks CVS, Medtronic and GSK, offering dividend yields of 3.02%-3.86% and varied ratings.
benzinga.com Why Is GSK Stock Gaining Monday? GSK shares jump over 4% on strong survival data for SCLC drug Ris-Rez and a 94% response rate for Jideytro in NSCLC.- benzinga.com GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows 94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).
benzinga.com 8 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
benzinga.com Why Is HUTCHMED Stock Soaring Thursday? HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
benzinga.com GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors GSK moves its dual-target mRNA seasonal flu vaccine to Phase 3 trials following strong Phase 2 data and FDA Fast Track status.
benzinga.com Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as traders see 89% odds of 4,000 U.S. cases.
benzinga.com Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
benzinga.com Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED) President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.- benzinga.com Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children https://youtu.be/H_RititNE8U
benzinga.com Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.